Barclays PLC Poseida Therapeutics, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Poseida Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 120,464 shares of PSTX stock, worth $1.15 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

120,464

Previous 120,464 -0.0%

Holding current value

$1.15 Million

Previous $345,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$2.7 - $4.04 $185,457 - $277,499	68,688 Added 132.66%	120,464 $345,000
Q2 2024 Aug 14, 2024	SELL	$2.0 - $3.46 $47,138 - $81,548	-23,569 Reduced 31.28%	51,776 $151,000
Q1 2024 May 15, 2024	SELL	$2.76 - $4.13 $126,937 - $189,946	-45,992 Reduced 37.9%	75,345 $240,000
Q4 2023 Feb 15, 2024	BUY	$1.83 - $3.51 $138,704 - $266,040	75,795 Added 166.43%	121,337 $408,000
Q3 2023 Nov 07, 2023	BUY	$1.62 - $2.79 $21,341 - $36,755	13,174 Added 40.7%	45,542 $109,000
Q2 2023 Aug 03, 2023	SELL	$1.66 - $3.4 $116,493 - $238,601	-70,177 Reduced 68.44%	32,368 $57,000
Q1 2023 May 04, 2023	BUY	$3.08 - $8.73 $136,862 - $387,926	44,436 Added 76.47%	102,545 $316,000
Q4 2022 Feb 13, 2023	BUY	$3.33 - $6.38 $88,744 - $170,027	26,650 Added 84.71%	58,109 $308,000
Q3 2022 Nov 03, 2022	BUY	$2.43 - $4.51 $4,514 - $8,379	1,858 Added 6.28%	31,459 $111,000
Q2 2022 Aug 12, 2022	SELL	$1.87 - $5.0 $8,411 - $22,490	-4,498 Reduced 13.19%	29,601 $76,000
Q1 2022 May 16, 2022	BUY	$3.22 - $7.04 $109,798 - $240,056	34,099 New	34,099 $152,000

Others Institutions Holding PSTX

# of Institutions

Shares Held

38.5M

Call Options Held

377K

Put Options Held

22.2K

View Full List

About Poseida Therapeutics, Inc.

Ticker PSTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,775,600
Market Cap $820M
Description
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant ...

More about PSTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account